Onychomysosis https://en.wikipedia.org/wiki/Onychomycosis
Onychomysosis Infectio fungalis unguium est. Indicium est discoloratio unguium vel flavus color, densitas ungui, separatio laminarum a lamina. Ungues affici possunt, plerumque ungues pedis. Complicationes includere possunt cellulitis cruris. Plures species fungorum onychomysosis causare possunt, inter dermatophyta. Factores periculosi includunt pedem athletae, morbos priores unguium, nuditatem cum morbis cutaneis, morbos vascularium periphericorum, immunitatem infirmam.

Antifungale medicamentum terbinafine ore administratum efficacissimum videtur, sed cum effectibus hepaticis lateralis coniungitur.

Onychomysosis circiter in 10 % populorum adultorum occurrit, cum senioribus frequentius afficitur. Viri saepius afficiuntur quam feminae. Onychomysosis repraesentat circiter dimidium omnium morborum unguium. Hoc significat deformitatem unguium etiam ex aliis causis, non solum ex onychomycosi, provenire.

○ Curatio OTC Medicamenta
Difficile est onychomycosim cum medicamentis topice tractare, quia difficile est medicamentis crassis per ungues penetrare.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate

○ Curatio
Longum tempus curatio requiri solet donec unguiculatum infectis penitus tollatur.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer
Informationes plurimae ― Latine
References Onychomycosis: Current trends in diagnosis and treatment 24364524
Curatio antifungalorum systemicorum valde efficax est. Meta‑analyses mycoticae rates sanationis ostendunt hoc modo: Terbinafine = 76 %, Itraconazole (dosis pulsata) = 63 %, Itraconazole (dosis continua) = 59 %, Fluconazole = 48 %. Concomitantia clavi debridementa rates remissionis amplius augent. Therapia topica cum ciclopirox sola minus efficax est; rata defectus 60 % superat.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
 Onychomycosis 28722883 
NIH
Onychomycosis est infectio fungalis quae ungues afficit. Cum dermatophyto causatur, tinea unguium appellatur. Onychomycosis includit infectiones a dermatophytis, fermentis et mollibus causatas. Unguis non infectus ex contagione fungali, qui appellatur nail dystrophy, est. Etiam si afficere potest ungues pedum et manus, toenail onychomycosis communior est. Hic articulus varias rationes toenail onychomycosis discutit, inter impulsum, genera clinica, gradus, diagnosis et curationem. Quamquam non minatur vitam, onychomycosis gravis complicationes ducere potest, sicut cellulitis, sepsis, infectio ossium, damnum textus, et damnum unguis.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
 Terbinafine 31424802 
NIH
Terbinafine medicamentum est, quod infectiones fungales pugnat, inhibens epoxidase squalenae. Efficax est contra multa genera fungorum cutis et approbatur ad tractandum onychomycem viva voce. Cum plures effectus lateris, sicut capitis et ventriculi, minores sunt et in se abeunt, mutationes in gustu (dysgeusia) variari possunt a levi ad gravem, interdum ad pondus damnum ducens. Mutationes gustus permanentes rarae sunt, sed mihi nuntiatae sunt.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
 Onychomycosis: An Updated Review 31738146 
NIH
Onychomycosis est infectio fungalis quae ungues afficit. Circa 90 % infectionum ungularum pedis et 75 % infectionum ungularum manuum a fungis causatur (Trichophyton mentagrophytes, Trichophyton rubrum). Signa includunt discolorationem unguis, crassitudinem, separationem a lamina unguis, et onycholysis. Curatio plerumque includit medicamentum orale, ut terbinafine vel itraconazole, cum therapia topica in casibus levibus.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.